Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study


Van Cutsem E., Boni C., Tabernero J., Massuti B., Middleton G., Dane F. , ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.26, sa.1, ss.149-156, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 26 Konu: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1093/annonc/mdu496
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Sayfa Sayıları: ss.149-156

Özet

Docetaxel/cisplatin/infusional 5-fluorouracil (5-FU; DCF) is a standard chemotherapy regimen for patients with advanced gastric cancer (GC). This phase II study evaluated docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/5-FU (TEF), and docetaxel/oxaliplatin/capecitabine (TEX) in patients with advanced GC.